Fulltext

Advanced drug delivery systems can assist in targeting coronavirus disease (COVID-19): A hypothesis

Mehta M 1 , Prasher P 2 , Sharma M 3 , Shastri MD 4 , Khurana N 5 , Vyas M 5 Show all authors , Dureja H 6 , Gupta G 7 , Anand K 8 , Satija S 1 , Chellappan DK 9 , Dua K 10

Affiliations 

  • 1 Discipline of Pharmacy, Graduate School of Health, University of Technology Sydney, Ultimo, NSW 2007, Australia; School of Pharmaceutical Sciences, Lovely Professional University, Phagwara 144411, Punjab, India
  • 2 Department of Chemistry, University of Petroleum & Energy Studies, Dehradun 248007, India
  • 3 Department of Chemistry, Uttaranchal University, Dehradun 248007, India
  • 4 School of Health Sciences, College of Health and Medicine, University of Tasmania, Launceston, TAS 7250, Australia
  • 5 School of Pharmaceutical Sciences, Lovely Professional University, Phagwara 144411, Punjab, India
  • 6 Faculty of Pharmaceutical Sciences, Maharshi Dayanand University, Rohtak, India
  • 7 School of Pharmacy, Suresh Gyan Vihar University, Jagatpura 302017, Mahal Road, Jaipur, India
  • 8 Department of Chemical Pathology, School of Pathology, Faculty of Health Sciences and National Health Laboratory Service, University of the Free State, Bloemfontein, South Africa
  • 9 Department of Life Sciences, School of Pharmacy, International Medical University, Bukit Jalil, 57000 Kuala Lumpur, Malaysia
  • 10 Discipline of Pharmacy, Graduate School of Health, University of Technology Sydney, Ultimo, NSW 2007, Australia; Priority Research Centre for Healthy Lungs, Hunter Medical Research Institute (HMRI) & School of Biomedical Sciences and Pharmacy, The University of Newcastle (UoN), Callaghan, NSW 2308, Australia; School of Pharmaceutical Sciences, Shoolini University, Bajhol, Sultanpur, Solan, Himachal Pradesh 173 229, India. Electronic address: Kamal.Dua@uts.edu.au
Med Hypotheses, 2020 Nov;144:110254.
PMID: 33254559 DOI: 10.1016/j.mehy.2020.110254

Abstract

The highly contagious coronavirus, which had already affected more than 2 million people in 210 countries, triggered a colossal economic crisis consequently resulting from measures adopted by various goverments to limit transmission. This has placed the lives of many people infected worldwide at great risk. Currently there are no established or validated treatments for COVID-19, that is approved worldwide. Nanocarriers may offer a wide range of applications that could be developed into risk-free approaches for successful therapeutic strategies that may lead to immunisation against the severe acute respiratory syndrome coronavirus 2 (SARS‑CoV‑2) which is the primary causative organism that had led to the current COVID-19 pandemic. We address existing as well as emerging therapeutic and prophylactic approaches that may enable us to effectively combat this pandemic, and also may help to identify the key areas where nano-scientists can step in.

* Title and MeSH Headings from MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

MeSH terms
Similar publications